medcelerator · clinician one-pager

Once-Daily Pill for FOP Bone Growth in Teens and Adults

Atebrioz (zilurgisertib) — oral ALK2 inhibitor to reduce new heterotopic ossification in FOP (ages 12+)

FDA Approved · United States · September 30, 2026

Condition: Fibrodysplasia Ossificans Progressiva

Who this is for

This is for teens 12 and older and adults with fibrodysplasia ossificans progressiva (FOP) — and caregivers — who need a labelled way to slow new extra bone (heterotopic ossification). It explains FDA approval of Atebrioz (zilurgisertib) tablets on 25 September 2026, the PROGRESS trial (NCT05090891), once-daily 100 mg oral dosing, Mirum Access Plus as the company access path when US supply starts, and why this is a different product from Pasatru (IV garetosmab) and Sohonos (palovarotene) — without treating a US bottle as another country’s carton or assuming every plan pays. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/atebrioz-zilurgisertib-fop